Literature DB >> 73064

Increased brain dopamine and reduced glutamic acid decarboxylase and choline acetyl transferase activity in schizophrenia and related psychoses.

E D Bird, E G Spokes, J Barnes, A V MacKay, L L Iversen, M Shepherd.   

Abstract

Dopamine, glutamic acid decarboxylase (G.A.D.) and choline acetyltransferase (C.A.T.) were measured in four regions of post-mortem brains. 41 patients with the hospital diagnosis of schizophrenia (psychotic group) were compared with a control grout normal in the putamen. G.A.D. activity was significantly reduced in the psychotic group, by about 50% in the nucleus accumbens, amygdala and hippocampus, and by about 30% in the putamen. C.A.T. activity was significantly lower in nucleus accumbens from the psychotic group, but normal in other brain regions. From an assessment of case notes, "schizophrenia" was distinguished from "schizophrenia-like psychosis". The biochemical findings for these subgroups were essentially similar, although C.A.T. activity in nucleus accumbens and hippocampus from the schizophrenic group was significantly lower than in controls. It is of brain are associated with schizophrenia and schizophrenia-like psychoses, although whether such neurochemical abnormalities are related to the illness or are a consequence of prolonged treatment with neuroleptic drugs remains unclear.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 73064     DOI: 10.1016/s0140-6736(77)91542-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  32 in total

1.  Bipolar disorder type 1 and schizophrenia are accompanied by decreased density of parvalbumin- and somatostatin-positive interneurons in the parahippocampal region.

Authors:  Alice Y Wang; Kathryn M Lohmann; C Kevin Yang; Eric I Zimmerman; Harry Pantazopoulos; Nicole Herring; Sabina Berretta; Stephan Heckers; Christine Konradi
Journal:  Acta Neuropathol       Date:  2011-10-04       Impact factor: 17.088

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

Review 4.  Transcriptional regulation of GAD1 GABA synthesis gene in the prefrontal cortex of subjects with schizophrenia.

Authors:  Amanda C Mitchell; Yan Jiang; Cyril Peter; Schahram Akbarian
Journal:  Schizophr Res       Date:  2014-10-31       Impact factor: 4.939

Review 5.  Using human brain imaging studies as a guide toward animal models of schizophrenia.

Authors:  S S Bolkan; F Carvalho Poyraz; C Kellendonk
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

Review 6.  Fifty Years of Research on Schizophrenia: The Ascendance of the Glutamatergic Synapse.

Authors:  Joseph T Coyle; W Brad Ruzicka; Darrick T Balu
Journal:  Am J Psychiatry       Date:  2020-12-01       Impact factor: 18.112

7.  NMDA receptor and schizophrenia: a brief history.

Authors:  Joseph T Coyle
Journal:  Schizophr Bull       Date:  2012-09       Impact factor: 9.306

8.  Neurochemical and genetic bases of psychopathology: current status.

Authors:  S S Kety
Journal:  Behav Genet       Date:  1982-02       Impact factor: 2.805

9.  Neurochemical heterogeneity of the primate nucleus accumbens.

Authors:  K Ikemoto; K Satoh; T Maeda; H C Fibiger
Journal:  Exp Brain Res       Date:  1995       Impact factor: 1.972

Review 10.  Structural plasticity of interneurons in the adult brain: role of PSA-NCAM and implications for psychiatric disorders.

Authors:  Juan Nacher; Ramon Guirado; Esther Castillo-Gómez
Journal:  Neurochem Res       Date:  2013-01-26       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.